---
title: "Pathophysiology Reference: Cardiovascular System Conditions"
type: "pathophysiology_monograph"
complexity: "elite_academic"
medical_specialty: ["Cardiology", "Internal Medicine"]
target_audience: ["Advanced Clinician", "Medical Researcher"]
systems: ["Cardiovascular System"]
conditions: ["Hypertension", "Atherosclerosis", "Heart Failure", "Myocardial Infarction"]
symptoms: ["Chest Pain", "Dyspnea", "Orthopnea", "Edema", "Palpitations", "Fatigue", "Claudication"]
biomarkers: ["Troponin I/T", "BNP", "NT-proBNP", "hs-CRP", "Lipid Panel", "Aldosterone/Renin Ratio"]
molecular_mechanisms: ["Endothelial Dysfunction", "RAAS Dysregulation", "Calcium Handling Defects", "Plaque Rupture", "Oxidative Stress"]
signaling_pathways: ["Renin-Angiotensin-Aldosterone System (RAAS)", "Nitric Oxide-cGMP Pathway", "Sympathetic Adrenergic Signaling", "Calcium-Calmodulin Pathway"]
drug_targets: ["ACE", "Angiotensin II Receptor (AT1)", "Beta-Adrenergic Receptors", "Calcium Channels", "HMG-CoA Reductase", "Neprilysin"]
clinical_significance: "critical_reference"
keywords: ["Afterload", "Preload", "Inotropy", "Lusitropy", "Frank-Starling Law", "Ischemia", "Remodeling", "Hypertrophy"]
summary: "A deep dive into the molecular and systemic pathology of cardiovascular diseases, focusing on hemodynamic mechanics, neurohormonal maladaptation, and the ischemic cascade."
last_updated: "2025-11-21"
---

# Pathophysiology Reference: Cardiovascular System Conditions

**Context:** This monograph provides an advanced pathophysiological analysis of cardiovascular diseases. It focuses on the molecular and systemic mechanisms driving hypertension, atherosclerosis, and heart failure, providing a rigorous foundation for clinical decision-making.

---

## Hypertension (Essential & Secondary)

### Etiology & Risk Factors
**Essential Hypertension (95%):** Multifactorial interplay of genetic and environmental factors.
*   **Genetics:** High heritability (30-50%). Polymorphisms in genes regulating the Renin-Angiotensin-Aldosterone System (RAAS) (e.g., *AGT*, *ACE*, *AGTR1*) and renal sodium handling (*ENaC*).
*   **Environmental:** High dietary sodium, obesity, chronic stress, physical inactivity.
**Secondary Hypertension (5%):** Renal artery stenosis, primary aldosteronism, pheochromocytoma, obstructive sleep apnea.

### Molecular & Cellular Pathogenesis
1.  **Endothelial Dysfunction:**
    *   **Mechanism:** Reduced bioavailability of **Nitric Oxide (NO)** due to oxidative stress (superoxide anions scavenging NO to form peroxynitrite).
    *   **Consequence:** Impaired vasodilation and increased expression of vasoconstrictors (**Endothelin-1**).
2.  **Vascular Smooth Muscle Cell (VSMC) Remodeling:**
    *   **Mechanism:** Altered calcium signaling (increased intracellular Ca$^{2+}$) and growth factor activation (PDGF, TGF-$\beta$).
    *   **Consequence:** VSMC hypertrophy and hyperplasia $\rightarrow$ increased wall-to-lumen ratio $\rightarrow$ increased Systemic Vascular Resistance (SVR).
3.  **RAAS Dysregulation:**
    *   **Angiotensin II:** Binds AT1 receptors $\rightarrow$ potent vasoconstriction + aldosterone release + superoxide production (via NADPH oxidase).

### Systemic Pathophysiology
**BP = Cardiac Output (CO) x Systemic Vascular Resistance (SVR)**
*   **Early Stage:** Increased CO (hyperkinetic state) driven by sympathetic overactivity.
*   **Established Hypertension:** Increased SVR with normal CO.
*   **Pressure-Natriuresis Resetting:** The kidney requires higher perfusion pressure to excrete a given sodium load (shift of the pressure-natriuresis curve to the right).
*   **Target Organ Damage:**
    *   **Cardiac:** Increased afterload $\rightarrow$ Left Ventricular Hypertrophy (LVH) $\rightarrow$ Diastolic Dysfunction.
    *   **Renal:** Glomerular hypertension $\rightarrow$ Glomerulosclerosis $\rightarrow$ CKD.
    *   **Cerebral:** Charcot-Bouchard microaneurysms $\rightarrow$ Hemorrhagic stroke.

### Pathophysiological Cascade
**[Flow: Hemodynamic Stress & End-Organ Damage]**
1.  **Initial Insult:** **Increased Systemic Vascular Resistance (SVR)** (due to endothelial dysfunction/sympathetic tone) OR **Volume Overload** (renal sodium retention).
2.  **Compensatory Response:** **Left Ventricular Hypertrophy (LVH)**. The heart thickens to normalize wall stress (Law of Laplace: Stress = Pressure Ã— Radius / Wall Thickness).
3.  **Maladaptive Consequence:**
    *   **Diastolic Dysfunction:** Thickened muscle is stiff $\rightarrow$ impaired filling.
    *   **Microvascular Rarefaction:** Capillary density doesn't keep up with muscle growth $\rightarrow$ subendocardial ischemia.
4.  **Symptom Mechanism:**
    *   **S4 Gallop:** Atria contract forcefully against stiff ventricle $\rightarrow$ audible vibration.
    *   **Headache:** Loss of cerebral autoregulation at high pressures $\rightarrow$ cerebral vasodilation/edema $\rightarrow$ traction on pain-sensitive meninges.

### Clinical Correlations
*   **"Silent Killer":** Asymptomatic until end-organ damage occurs.
*   **S4 Gallop:** Atrial contraction against a stiff, hypertrophied ventricle (diastolic dysfunction).
*   **Retinopathy:** Arteriolar narrowing (copper wiring), AV nicking, cotton-wool spots, papilledema (malignant hypertension).
*   **Headache:** Occipital, typically morning (severe cases).

### Diagnostic Biomarkers
*   **Urinalysis:** Microalbuminuria (early renal damage).
*   **Serum Creatinine/eGFR:** Renal function.
*   **Aldosterone/Renin Ratio (ARR):** Screen for primary aldosteronism if resistant.
*   **Plasma Metanephrines:** Screen for pheochromocytoma.

---

## Atherosclerosis

### Etiology & Risk Factors
A chronic inflammatory disease of the arterial wall initiated by endothelial injury.
*   **Major Risk Factors:** Dyslipidemia (High LDL, Low HDL), Hypertension, Smoking, Diabetes, Homocysteine.

### Molecular & Cellular Pathogenesis
**Response-to-Injury Hypothesis:**
1.  **Endothelial Injury:** Increases permeability and expression of adhesion molecules (VCAM-1, ICAM-1).
2.  **Lipid Infiltration:** LDL cholesterol enters the subendothelial space (intima) and undergoes **oxidation** (oxLDL).
3.  **Inflammation:** Monocytes adhere to endothelium, migrate into intima, and differentiate into macrophages.
4.  **Foam Cell Formation:** Macrophages ingest oxLDL via scavenger receptors (SR-A, CD36). Unlike LDL receptors, these are not downregulated by intracellular cholesterol $\rightarrow$ massive accumulation $\rightarrow$ **Foam Cells**.
5.  **Fibrous Cap Formation:** VSMCs migrate from media to intima, proliferate, and secrete collagen to stabilize the plaque.

### Systemic Pathophysiology
*   **Stenosis:** Gradual luminal narrowing. Hemodynamically significant at >70% occlusion $\rightarrow$ ischemia during demand (Stable Angina).
*   **Plaque Rupture:** The critical event.
    *   **Vulnerable Plaque:** Large lipid core, thin fibrous cap, high inflammatory cell content (macrophages secrete metalloproteinases that degrade collagen).
    *   **Thrombosis:** Rupture exposes highly thrombogenic subendothelial matrix (Tissue Factor) $\rightarrow$ platelet aggregation $\rightarrow$ thrombus formation $\rightarrow$ acute occlusion.

### Pathophysiological Cascade
**[Flow: Ischemia & Plaque Rupture]**
1.  **Initial Insult:** **Endothelial Injury** allows LDL infiltration and oxidation.
2.  **Compensatory Response:** **Fibrous Cap Formation**. VSMCs migrate to cover the lipid core, attempting to "wall off" the inflammation.
3.  **Maladaptive Consequence:** **Luminal Narrowing**. The plaque grows inward.
    *   **Stable Angina:** Plaque obstructs >70% of lumen $\rightarrow$ flow reserve exhausted during exertion $\rightarrow$ supply/demand mismatch.
4.  **Symptom Mechanism:**
    *   **Angina Pectoris:** Ischemic myocytes release **Adenosine** and **Bradykinin** $\rightarrow$ stimulate sympathetic afferent nerve fibers $\rightarrow$ perceived as crushing chest pain.

### Clinical Correlations
*   **Stable Angina:** Exertional chest pain relieved by rest/nitroglycerin (demand ischemia).
*   **Acute Coronary Syndrome (ACS):** Unstable angina, NSTEMI, STEMI (supply ischemia due to thrombus).
*   **Claudication:** Exertional leg pain (Peripheral Arterial Disease).
*   **Xanthomas:** Lipid deposits in skin/tendons (Familial Hypercholesterolemia).

### Diagnostic Biomarkers
*   **Lipid Panel:** LDL-C (>100 mg/dL), HDL-C (<40 mg/dL), Triglycerides.
*   **hs-CRP:** High-sensitivity C-reactive protein (marker of vascular inflammation).
*   **Coronary Calcium Score:** CT imaging of calcified plaque burden.
*   **Lipoprotein(a):** Genetic risk factor.

---

## Heart Failure (HF)

### Etiology & Risk Factors
The inability of the heart to pump blood sufficient to meet metabolic needs.
*   **HFrEF (Systolic):** CAD (MI), Dilated Cardiomyopathy, Valvular Regurgitation.
*   **HFpEF (Diastolic):** Hypertension (LVH), Aging, Restrictive Cardiomyopathy.

### Molecular & Cellular Pathogenesis
**Ventricular Remodeling:**
*   **Cardiomyocyte Hypertrophy:** Pathologic growth.
    *   **Concentric:** Sarcomeres added in parallel (pressure overload/HTN) $\rightarrow$ wall thickening.
    *   **Eccentric:** Sarcomeres added in series (volume overload/regurgitation) $\rightarrow$ dilation.
*   **Apoptosis:** Programmed cell death of cardiomyocytes.
*   **Fibrosis:** Activation of cardiac fibroblasts $\rightarrow$ collagen deposition $\rightarrow$ stiffness.
*   **Calcium Handling Defect:** Impaired SERCA2a function $\rightarrow$ reduced Ca$^{2+}$ reuptake into SR $\rightarrow$ impaired relaxation and weak contraction.

### Systemic Pathophysiology
**Neurohormonal Activation (Compensatory $\rightarrow$ Maladaptive):**
1.  **Sympathetic Nervous System (SNS):** Increases HR and contractility. Chronic activation $\rightarrow$ $\beta$-receptor downregulation and toxicity.
2.  **RAAS Activation:** Angiotensin II (vasoconstriction) + Aldosterone (volume retention). Increases preload and afterload, further stressing the failing heart.
3.  **Natriuretic Peptides (ANP/BNP):** Released by stretched atria/ventricles. Beneficial effects (vasodilation, natriuresis) but overwhelmed in advanced HF.

### Pathophysiological Cascade
**[Flow: The Vicious Cycle of Compensation]**
1.  **Initial Insult:** **Reduced Cardiac Output (CO)** (due to pump failure).
2.  **Compensatory Response:**
    *   **Sympathetic Surge:** $\uparrow$ HR and Contractility to maintain CO.
    *   **RAAS Activation:** Angiotensin II constricts arterioles ($\uparrow$ BP) and Aldosterone retains Na+/H2O ($\uparrow$ Blood Volume) to maintain perfusion pressure.
3.  **Maladaptive Consequence:**
    *   **Increased Afterload:** Failing heart pumps against higher resistance.
    *   **Volume Overload:** Fluid backs up into lungs/venous system.
4.  **Symptom Mechanism:**
    *   **Pulmonary Edema (Dyspnea):** Left atrial pressure rises $\rightarrow$ pulmonary capillary hydrostatic pressure > oncotic pressure $\rightarrow$ fluid leaks into alveoli $\rightarrow$ impaired gas exchange.
    *   **Peripheral Edema:** Right atrial pressure rises $\rightarrow$ systemic venous hydrostatic pressure rises $\rightarrow$ fluid leaks into interstitial tissue (gravity-dependent).

### Clinical Correlations
*   **Left-Sided HF:**
    *   **Backward Failure:** Pulmonary congestion $\rightarrow$ Dyspnea, Orthopnea, Paroxysmal Nocturnal Dyspnea (PND), Crackles.
    *   **Forward Failure:** Reduced perfusion $\rightarrow$ Fatigue, Confusion, Renal failure.
*   **Right-Sided HF:**
    *   **Backward Failure:** Systemic congestion $\rightarrow$ JVD, Hepatomegaly, Ascites, Peripheral Edema.
    *   **Cor Pulmonale:** Right HF due to pulmonary hypertension.

### Diagnostic Biomarkers
*   **BNP / NT-proBNP:** Released from ventricles in response to stretch. High negative predictive value.
*   **Echocardiogram:** Gold standard for Ejection Fraction (EF) and structural assessment.
*   **Troponin:** To rule out acute ischemia as precipitant.

---

## Myocardial Infarction (MI)

### Etiology
Acute necrosis of myocardium due to prolonged ischemia.
*   **Type 1 MI:** Spontaneous plaque rupture/erosion with thrombosis (classic heart attack).
*   **Type 2 MI:** Ischemia due to supply/demand mismatch (e.g., severe anemia, hypotension, tachyarrhythmia) without plaque rupture.

### Molecular Pathogenesis
*   **Ischemic Cascade:**
    1.  **Metabolic Switch:** Aerobic $\rightarrow$ Anaerobic metabolism. Lactate accumulation.
    2.  **ATP Depletion:** Failure of Na+/K+ ATPase $\rightarrow$ cellular swelling.
    3.  **Calcium Overload:** Cytosolic Ca$^{2+}$ accumulation $\rightarrow$ protease activation.
    4.  **Cell Death:** Irreversible injury occurs after **20-40 minutes** of complete occlusion. Necrosis triggers intense inflammatory response.

### Systemic Pathophysiology
*   **Systolic Dysfunction:** Loss of contractile mass $\rightarrow$ reduced EF $\rightarrow$ cardiogenic shock.
*   **Diastolic Dysfunction:** Ischemic stiffness $\rightarrow$ pulmonary congestion.
*   **Electrical Instability:** Ischemic tissue is arrhythmogenic $\rightarrow$ VT/VF (primary cause of pre-hospital death).

### Pathophysiological Cascade
**[Flow: Acute Ischemia & Necrosis]**
1.  **Initial Insult:** **Plaque Rupture** $\rightarrow$ Thrombus formation $\rightarrow$ Complete coronary occlusion.
2.  **Compensatory Response:** **Anaerobic Metabolism**. Myocytes switch to glycolysis to generate ATP.
3.  **Maladaptive Consequence:**
    *   **Acidosis:** Lactate accumulates $\rightarrow$ intracellular pH drops $\rightarrow$ contractile failure.
    *   **Ion Pump Failure:** No ATP $\rightarrow$ Na+/K+ ATPase stops $\rightarrow$ cell swells.
    *   **Membrane Rupture:** Intracellular contents (Troponin, CK-MB) leak into blood.
4.  **Symptom Mechanism:**
    *   **Diaphoresis/Nausea:** Severe pain + ischemic metabolites trigger massive autonomic discharge (sympathetic + vagal).
    *   **Dyspnea:** Acute diastolic stiffness (ischemic relaxation failure) $\rightarrow$ rapid rise in LA pressure $\rightarrow$ flash pulmonary edema.

### Clinical Correlations
*   **Chest Pain:** Retrosternal, crushing ("elephant on chest"), radiating to left arm/jaw.
*   **Autonomic Symptoms:** Diaphoresis, nausea/vomiting (vagal stimulation, common in inferior MI).
*   **Levine's Sign:** Clenched fist over chest.

### Diagnostic Biomarkers
*   **Cardiac Troponin (cTnI/cTnT):** Gold standard. Rises 3-4h, peaks 24h, persists 7-10 days.
*   **CK-MB:** Useful for detecting re-infarction (returns to normal in 48-72h).
*   **ECG:**
    *   **STEMI:** ST-segment elevation (transmural injury).
    *   **NSTEMI:** ST depression, T-wave inversion (subendocardial injury).
